Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity is a research paper published in Science Translational Medicine (2021). On theSindex it has a DataRank of 0. It has been cited 80 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01HL149954
National Institutes of Health
Grant: R01HL55337
National Institutes of Health
Grant: R01HL119291
National Institutes of Health
Grant: K08HL135400
National Institutes of Health
Grant: 00060337
NHLBI NIH HHS
Grant: R01 HL055337
NCI NIH HHS
Grant: P30 CA091842
MeSH Terms
Additional file 4 of Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1
Additional file 5 of Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1
Additional file 4 of Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1
Additional file 5 of Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1
Additional file 1 of Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1
Additional file 2 of Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1
Additional file 2 of Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1
Additional file 3 of Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1
Additional file 1 of Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1
Additional file 3 of Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1
Additional file 1 of Mortalin promotes the evolution of androgen-independent prostate cancer through Wnt/β-catenin signaling pathway
Additional file 1 of Mortalin promotes the evolution of androgen-independent prostate cancer through Wnt/β-catenin signaling pathway